Shattuck Labs director acquires 128K shares via warrants
Shattuck Labs director Clay B. Siegall increased his direct stake by exercising warrants for common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Shattuck Labs director Clay B. Siegall increased his direct stake by exercising warrants for common stock. On May 22, 2026, he acquired 128,054 shares of common stock at an exercise price of $1.0846 per share through the exercise of warrants.
These warrants were originally issued in a private placement under an August 4, 2025 securities purchase agreement, where he bought 128,054 shares of common stock with accompanying warrants at a combined price of $0.8677 per share and warrant. Following the latest transactions, Siegall directly holds 256,108 common shares, with the exercised warrants position reduced to zero.
Insider Trade Summary
128,054 shares exercised/converted
Exercise
2 txns
Insider
SIEGALL CLAY B
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Warrants (Right to Buy) | 128,054 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 128,054 | $1.0846 | $139K |
Holdings After Transaction:
Warrants (Right to Buy) — 0 contracts (Direct);
Common Stock — 256,108 shares (Direct)
Footnotes (2)
- F1. On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 128,054 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 128,054 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.
- F2. The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.
Key Figures
Common shares acquired: 128,054 shares
Exercise price: $1.0846 per share
Shares held after transaction: 256,108 shares
+2 more
5 metrics
Common shares acquired
128,054 shares
Acquired on May 22, 2026 via warrant exercise
Exercise price
$1.0846 per share
Conversion or exercise price of warrants
Shares held after transaction
256,108 shares
Total direct common stock ownership post-transaction
Warrants exercised
128,054 warrants
Derivative securities converted into common stock
Original private placement price
$0.8677 per unit
Combined price per share and accompanying warrant in 2025 placement
Key Terms
securities purchase agreement, private placement, Warrants, Phase 1 clinical trial, +1 more
5 terms
securities purchase agreement financial
"the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
private placement financial
"the Issuer in a private placement, which closed on August 25, 2025, issued and sold"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Warrants financial
"accompanying warrants (the "Warrants") to purchase up to an aggregate of 128,054 shares"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
Phase 1 clinical trial medical
"the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data"
A phase 1 clinical trial is the first stage of testing a new drug or treatment in people, typically involving a small group to assess safety, how the body handles the treatment, and appropriate dosing. For investors, phase 1 results are an early risk check — like a test drive that can reveal fatal flaws or promising signals — and they often cause big changes in a drug’s perceived value and the company’s prospects.
exercise or conversion of derivative security financial
"transaction code description: Exercise or conversion of derivative security"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Shattuck Labs (STTK) director Clay B. Siegall report in this Form 4?
Clay B. Siegall reported acquiring 128,054 Shattuck Labs common shares. He obtained these shares on May 22, 2026 by exercising previously issued warrants, bringing his direct holdings to 256,108 common shares after the transactions disclosed.
What was the exercise price for the Shattuck Labs (STTK) warrants in this Form 4?
The exercised warrants carried a conversion or exercise price of $1.0846 per share. Siegall used these warrants to acquire 128,054 common shares at that price, with the derivative position reduced to zero following the exercise.
How were the Shattuck Labs (STTK) warrants originally issued to Clay B. Siegall?
The warrants came from an August 4, 2025 securities purchase agreement. In that private placement, Shattuck Labs sold Siegall 128,054 common shares plus accompanying warrants at a combined price of $0.8677 per share and warrant, closing on August 25, 2025.
What happens to Clay B. Siegall’s Shattuck Labs (STTK) warrants after this transaction?
The reported warrant position drops to zero after the exercise. Siegall exercised 128,054 warrants into 128,054 common shares at an exercise price of $1.0846, leaving no remaining warrants shown in this filing’s derivative summary.
AI-generated analysis. How Rhea-AI works. Not financial advice.
